Long-term treatment of hypercholesterolemia with colestipol hydrochloride

Clin Pharmacol Ther. 1975 Jan;17(1):83-7. doi: 10.1002/cpt197517183.

Abstract

Colestipol hydroxhloride (15 gm/day) (an anion exchange resin that binds bile acids) of placebo was administered to 92 patients with hypercholesterolemia who were followed for periods up to 36 months. There was a prompt (1 month), significant (p smaller than 0.05 minus 0.001), and sustained (36 months) lowering of serum cholesterol in the colestipol HCl-treated group, but no significant change in the placebo group. Serum triglycerides increased in both treatment groups in parallel; the reason was not apparent. Side effects were equally distributed between colestipol HCl and placebo and were primarily gastrointestinal (upper abdominal distress, constipation). Colestipol HCl appears to be a safe and effective treatment for hypercholesterolemia; tolerance does not seem to develop.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Cellulose / therapeutic use
  • Cholesterol / blood
  • Clinical Trials as Topic
  • Diabetes Complications
  • Drug Tolerance
  • Ethers, Cyclic / adverse effects
  • Ethers, Cyclic / therapeutic use*
  • Female
  • Humans
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / drug therapy*
  • Male
  • Middle Aged
  • Placebos
  • Polyamines / adverse effects
  • Polyamines / therapeutic use*
  • Polymers / adverse effects
  • Polymers / therapeutic use
  • Time Factors
  • Triglycerides / blood

Substances

  • Ethers, Cyclic
  • Placebos
  • Polyamines
  • Polymers
  • Triglycerides
  • Cellulose
  • Cholesterol